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BRIEF COMMUNICATION
PROPOSAL OF ABOLITION OF THE SKIN SENSITIVITY TEST BEFORE EQUINE RABIES
IMMUNE GLOBULIN APPLICATION
Palmira CUPO(1), Marisa M. de AZEVEDO-MARQUES(2), Willy SARTI(2) & Sylvia Evelyn HERING(1)
SUMMARY
An epizootic outbreak of rabies occurred in 1995 in Ribeirão Preto, SP, with 58 cases of animal rabies (54 dogs, 3 cats and 1 bat)
confirmed by the Pasteur Institute of São Paulo, and one human death. The need to provide care to a large number of people for the
application of equine rabies immune globulin (ERIG) prevented the execution of the skin sensitivity test (SST) and often also the
execution of desensitization, procedures routinely used up to that time at the Emergency Unit of the University Hospital of the Faculty
of Medicine of Ribeirão Preto, University of São Paulo (EU-UHFMRP-USP), a reference hospital for the application of heterologous
sera. In view of our positive experience of several years with the abolition of SST and of the use of premedication before the
application of antivenom sera, we used a similar schedule for ERIG application. Of the 1489 victims of animal bites, 1054 (71%)
received ERIG; no patient was submitted to SST and all received intravenously anti-histamines (anti-H1 + anti-H2) and corticosteroids
before the procedure. The patients were kept under observation for 60 to 180 minutes and no adverse reaction was observed. On the
basis of these results, since December 1995 ERIG application has been decentralized in Ribeirão Preto and has become the responsibility
of the Emergency Unit of the University Hospital and the Central Basic Health Unit, where the same routine is used. Since then, 4216
patients have received ERIG (1818 at the Basic Health Unit and 2398 at the EU-UHFMRP), with no problems.
The ideal would be the routine use of human rabies immune globulin (HRIG) in public health programs, but this is problematic,
because of their high cost. However, while this does not occur, the use of SST is no longer justified at the time of application of ERIG,
in view of the clinical evidence of low predictive value and low sensitivity of SST involving the application of heterologous sera. It is
very important to point out that a negative SST result may lead the health team to a feeling of false safety that no adverse reaction will
occur, but this is not true for the anaphylactoid reactions.
The decision to use premedication, which is based on knowledge about anaphylaxis and on the pharmacology of the medication
used, is left to the judgment of health professionals, who should always be prepared for eventual untoward events.
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An epizootic rabies outbreak occurred in 1995 in Ribeirão Preto,
SP, with 58 cases of animal rabies (54 dogs, 3 cats and 1 bat) confirmed
by the Pasteur Institute, São Paulo, and one human death. The Emergency
Unit of the University Hospital of the Faculty of Medicine of Ribeirão
Preto, University of São Paulo (EU-UHFMRP-USP), a tertiary reference
hospital for the emergency care of a population from a geographical
area of 1,000,000 inhabitants, and also a reference hospital for the
application of heterologous sera, was faced by the need to provide care
to a large number of people (with no disease!) for equine rabies immune
globulin (ERIG) application. The occurrence of this new situation,
together with the impossibility of predicting the extent and duration of
the epizootic, made impossible the routine application of ERIG following
skin sensitivity test (SST) as done previously2,11.
In view of our positive experience of many years with the abolition
of the SST before the intravenous application of antivenom sera (AVS)
(because their low sensitivity and predictive value) and with the use of
premedication, we decided to use an identical scheme for ERIG
application4. Since we were convinced of the benefits of premedication
as a safe measure for protection against possible and potentially serious
reactions, we felt that we could not ethically conduct a controlled study,
and all patients received the premedication according to the routine
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established in our service for AVS application: intravenous administration
of antihistamines (anti-H1+ anti-H2) and hydrocortisone.
The immediate reactions that might occur with the use of
heterologous sera may be mediated by IgE and can be detected by SST
(anaphylactic reactions) or are triggered by complement activation, non-
immunological activation of mast cells or of the modulators of
arachidonic acid and do not depend on previous exposure to antigens
(anaphylactoid reactions). These are not detected by SST1,17. The clinical
manifestations of these two types of immediate reactions are similar,
thus preventing inferences about the immunopathological mechanism
involved.
In order to prevent or attenuate possible immediate reactions in risk
situations, the use of anti-histamines (anti-H1 + anti-H2) and
corticosteroids is recommended, with the latter acting as anti-
inflammatory agent in the attempt to inhibit late manifestations of
immediate hypersensitivity, reducing the continued release of
inflammatory mediators, complement activation and vascular aggression,
and having no immunosuppressive effect at the dose used1,17.
A total of 1489 patients were seen at the EU-UHFMRP-USP from
January to December 1995. Of these, 695 received only ERIG (because
they had already received the first dose of vaccination before coming to
the hospital), 359 received ERIG plus vaccination, and 435 were only
vaccinated. The patients who received ERIG were kept under observation
for 60-180 minutes and showed no adverse reaction. They were then
referred back to their Basic Health Units of origin to complete the
vaccination schedule and were instructed to return to the hospital if any
complication should occur. The ERIG utilized were from 5 different
sources: Butantan Institute (São Paulo), Vital Brazil Institute (Rio de
Janeiro), National Health Institute (Colombia), Pasteur Institute (Paris),
and Swiss Serum and Vaccine Institute (Switzerland)5.
On the basis of the data obtained and in collaboration with the
Municipal Health Secretariat of Ribeirão Preto, since December 1995
the application of ERIG has been decentralized and the patients from
the city of Ribeirão Preto are instructed to look for the Central Basic
Health Unit to receive ERIG. EU-UHFMRP-USP continues to be
responsible for providing care to the patients coming from the 23 towns
belonging to the Health Macroregion. The same routine was used at the
two health units, e.g. use of premedication and without SST. From January
1995 to December 1999, 2398 patients received ERIG at the EU-
UHFMRP-USP, and from December 1995 to December 1999, 1818
patients have received ERIG at the Central Basic Health Unit, for a total
of 4216 patients. No adverse reactions have been observed.
With the use of purified ERIG the incidence of adverse reactions
has been low (0.8%-6%), and most of those that occurred were minor,
and relationated to local reactions and serum sickness14,15,16. The incidence
of early manifestations is calculated to be less than 1:35,000 treatments10.
Anaphylactic and anaphylactoid episodes have been reported to occur
during desensitization or in patients with negative skin tests7,15. In Brazil,
there are few reports of anaphylaxis among patients not submitted to
SST or to premedication3,6.
Recommendations for methods of administering skin tests and for
its interpretation vary greatly. The standardization and validity of SST
for predicting reactions to ERIG were discussed in a report on 150 patients
with a positive SST who received ERIG without prior desensitization
and under close supervision without problems10.
The Report of WHO Consultation on Intradermal Application of
Human Rabies Vaccines (1995)12 recommends that the SST should no
longer be used before ERIG, because there is no evidence that he predicts
anaphylaxis or serum sickness reactions, suggesting instead direct serum
application, with care taken to treat possible untoward effect. In 1997,
the WHO13 recommendation is that if the SST is positive, treatment with
ERIG or preferably human rabies immune globulin should proceed if
indicated, but special precautions should be taken if ERIG are used (e.g.
pretreatment with adrenaline/epinephrine i.m. and with antihistamine)
and the patient observed for at least one hour after the injection. Because
techniques of skin testing have been not standardized the WHO
recommends that national guidelines should be followed.
The ideal would be the routine use of HRIG in public health programs,
but this is problematic, because of the high cost of HRIG. However,
while this does not occur the use of SST is no longer justified at the time
of application of ERIG, in view of the evidence of low predictive value
and low sensitivity of SST involving the application of heterologous
sera4,10.
The administration of premedication is based on knowledge about
the physiopathology of anaphylaxis and on the pharmacology of the
medications used1,8,17. It is a process free from side effects and relatively
inexpensive if we consider the time saved by the health professionals
involved in the execution of the SST and desensitization (a painful, slow
and not risk-free process)9, in addition to avoiding discomfort to the
patient. It is very important to point out that a negative SST result may
lead the health team to a feeling of false safety that no adverse reaction
will occur, but this is not true for anaphylactoid reactions.
The decision to utilize premedication is left to the judgment of health
professionals, with the patient being kept under observation for 1 to 2
hours in any case, so that any adverse reaction may be immediately
reversed.
RESUMO
Proposta de abolição do teste de sensibilidade cutâneo antes da
aplicação do soro anti-rábico de origem eqüina
Durante o ano de 1995, ocorreu em Ribeirão Preto, SP, uma epizootia
de raiva, com 58 casos de raiva animal (54 cães, 3 gatos, 1 morcego),
confirmados pelo Instituto Pasteur, S. Paulo, e um óbito humano. A
necessidade de prestar atendimento a um grande número de pessoas para
aplicação do soro anti-rábico eqüino, tornou inviável a realização do
teste de sensibilidade intradérmico (TSI) e da dessensibilização, utilizados
até então como rotina, conforme orientação da Organização Mundial da
Saúde e do Ministério da Saúde, na Unidade de Emergência do Hospital
das Clínicas da Faculdade de Medicina de Ribeirão Preto, hospital de
referência para aplicação de soros heterólogos. Com base na experiência
positiva de vários anos com a abolição do TSI e uso de pré-medicação
antes da aplicação endovenosa de soros antivenenos, foi utilizado
esquema semelhante para a aplicação de soro anti-rábico eqüino (SARE).
Das 1489 vítimas de mordeduras de animais, 1054 (71%) receberam
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SARE; nenhuma delas foi submetida ao TSI e todas receberam
previamente anti-histamínicos (anti-H1 + anti-H2) e corticosteróides por
via intravenosa, permanecendo em observação durante 60 a 180 minutos,
não sendo verificada nenhuma reação adversa. A partir desses resultados,
desde dezembro de 1995 a aplicação do SARE foi descentralizada em
Ribeirão Preto, ficando responsável a Unidade Básica de Saúde Central
(UBDS) pelos pacientes moradores da cidade de Ribeirão Preto, e a
Unidade de Emergência do Hospital das Clínicas, pelos provenientes
das cidades componentes da macroregião, utilizando-se a mesma rotina
nesses dois locais, ou seja, abolição do TSI e uso de pré-medicação.
Desde então até dezembro de 1999, 4216 pacientes receberam SARE,
sem problemas (2398 na UE-HCFMRP e 1818 na UBDS).
O ideal seria a possibilidade de utilização de imunoglobulina anti-
rábica humana nos programas de saúde pública, o que é problemático
devido ao seu alto custo. Enquanto isso não ocorrer, a realização de TSI
quando da aplicação de SARE não mais se justifica, devido às evidências
do baixo valor preditivo e baixa sensibilidade dos TSI frente à aplicação
de soros heterólogos. Mais importante ainda, um TSI negativo pode dar
ao profissional de saúde a falsa segurança de que não ocorrerá nenhuma
reação, o que não é válido para as reações anafilactóides.
A decisão da utilização de pré-medicação, que se baseia no
conhecimento da fisiopatologia da anafilaxia e na farmacologia da
medicação utilizada, fica a critério do profissional de saúde, que deve
sempre estar preparado para eventuais intercorrências.
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